ImageneBio (IMA) expands board to 7; names Audit Chair Nov 18

ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025.

Accepted by SEC EDGAR 11/05/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025. He will serve as Chair of the Audit Committee effective November 18, 2025.

The company entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to its Form S-1.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IMA announce in this 8-K?

ImageneBio increased its Board size to seven and appointed Joseph P. Slattery as a director effective November 1, 2025.

What role will Joseph P. Slattery hold at IMA?

He will be Chair of the Audit Committee effective November 18, 2025.

How many directors does ImageneBio (IMA) have now?

The Board now has seven directors.

When is Joseph P. Slattery’s board appointment effective?

His appointment as director is effective November 1, 2025.

Did IMA enter into an indemnification agreement with the new director?

Yes. The company entered into its standard indemnification agreement with Mr. Slattery.

Which committee will Joseph P. Slattery lead at IMA?

He will lead the Audit Committee starting November 18, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASDAQ false 0001835579 0001835579 2025-11-01 2025-11-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive, Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 345-6265

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

On November 1, 2025, the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”) increased the authorized size of the Board from six directors to seven directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Joseph P. Slattery to the Board, effective November 1, 2025, and as the Chair of the Audit Committee of the Board, effective November 18, 2025.

The Company has entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 (No. 333-290108), filed with the SEC on September 8, 2025.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: November 5, 2025				By:		/s/ Kristin Yarema
						Kristin Yarema, Ph.D.
						Chief Executive Officer